Browse

CD24, a Novel Cancer Biomarker, Predicting Disease-Free Survival of Non-small Cell Lung Carcinomas A Retrospective Study of Prognostic Factor Analysis from the Viewpoint of Forthcoming (Seventh) New TNM Classification

DC Field Value Language
dc.contributor.authorLee, Hyun Ju-
dc.contributor.authorChoe, Gheeyoung-
dc.contributor.authorJheon, Sanghoon-
dc.contributor.authorSung, Sook-Whan-
dc.contributor.authorChung, Jin-Haeng-
dc.contributor.authorLee, Choon-Taek-
dc.date.accessioned2012-05-31T05:21:02Z-
dc.date.available2012-05-31T05:21:02Z-
dc.date.issued2010-05-
dc.identifier.citationJOURNAL OF THORACIC ONCOLOGY; Vol.5 5; 649-657ko_KR
dc.identifier.issn1556-0864-
dc.identifier.urihttp://hdl.handle.net/10371/76673-
dc.description.abstractIntroduction: Metastasis-associated protein CD24 has been identified as a new prognostic factor and stem cell marker in the human neoplasm. However, the importance of the CD24 in non-small cell lung carcinomas (NSCLCs) has not been elucidated well. Methods: We evaluated CD24 expression in 267 consecutive cases of NSCLC by immunohistochemistry using a tissue microarray technique and correlated with clinicopathologic parameters including forthcoming (seventh) new tumor node metastasis classification. Results: CD24-high expression was demonstrated in 87 of 267 (33%) and was associated with adenocarcinoma (ADC) histology than in squamous cell carcinoma histology (64 of 165 [39%] vs. 20 of 88 [23%]; p = 0.023). Patients with CD24-high tumors tended to have a higher risk of disease progression (p < 0.001) and cancer-related death (p = 0.002). Multivariate analysis proved CD24-high expression as independent prognostic factors of disease progression and cancer-related death (p = 0.002, hazard ratio = 1.78, 95% confidence interval = 1.23-2.58 and p = 0.017, hazard ratio = 1.93, 95% confidence interval = 1.13-3.31). CD24-high expression had a tendency to correlate with new pathologic stage (p-stage) (p = 0.089) rather than old p-stage (p = 0.253). Performance status and new p-stage, regardless of the tumor histology, were identified as consistent independent prognostic factors of disease progression and cancer-related death. However, age was related to a significantly shorter cancer-specific survival in ADC only. Conclusions: CD24 expression in NSCLC is associated with ADC histology and disease progression and cancer-related death, indicative of aggressive tumor behavior. Performance status and new p-stage, to a lesser extent, age correlated with progression-free survival and cancer-specific survival, regardless of tumor histology.ko_KR
dc.language.isoenko_KR
dc.publisherLIPPINCOTT WILLIAMS & WILKINSko_KR
dc.subjectCarcinomako_KR
dc.subjectCD24ko_KR
dc.subjectPrognostic factorsko_KR
dc.subjectPathologic stageko_KR
dc.subjectPrognosisko_KR
dc.subjectNon-small cell lungko_KR
dc.subjectImmunohistochemistryko_KR
dc.titleCD24, a Novel Cancer Biomarker, Predicting Disease-Free Survival of Non-small Cell Lung Carcinomas A Retrospective Study of Prognostic Factor Analysis from the Viewpoint of Forthcoming (Seventh) New TNM Classificationko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor이현주-
dc.contributor.AlternativeAuthor최기영-
dc.contributor.AlternativeAuthor전상훈-
dc.contributor.AlternativeAuthor성숙환-
dc.contributor.AlternativeAuthor이춘택-
dc.contributor.AlternativeAuthor정진행-
dc.identifier.doi10.1097/JTO.0b013e3181d5e554-
dc.citation.journaltitleJOURNAL OF THORACIC ONCOLOGY-
dc.description.citedreferenceYoo SB, 2010, LUNG CANCER, V67, P301, DOI 10.1016/j.lungcan.2009.05.002-
dc.description.citedreferenceXu X, 2010, J THORAC ONCOL, V5, P39-
dc.description.citedreferenceChung JH, 2009, J THORAC ONCOL, V4, P1490-
dc.description.citedreferenceTirino V, 2009, EUR J CARDIO-THORAC, V36, P446, DOI 10.1016/j.ejcts.2009.03.063-
dc.description.citedreferenceChansky K, 2009, J THORAC ONCOL, V4, P792-
dc.description.citedreferenceTravis WD, 2009, HISTOPATHOLOGY, V54, P3, DOI 10.1111/j.1365-2559.2008.03179.x-
dc.description.citedreferenceLEE HJ, 2009, LUNG CANC 0825-
dc.description.citedreferenceLee HJ, 2008, UROLOGY, V72, P603, DOI 10.1016/j.urology.2008.01.061-
dc.description.citedreferenceSculier JP, 2008, J THORAC ONCOL, V3, P457-
dc.description.citedreferenceMyung JK, 2008, LUNG CANCER, V59, P198, DOI 10.1016/j.lungcan.2007.08.023-
dc.description.citedreferenceGroome PA, 2007, J THORAC ONCOL, V2, P694-
dc.description.citedreferenceGoldstraw P, 2007, J THORAC ONCOL, V2, P706-
dc.description.citedreferencePostmus PE, 2007, J THORAC ONCOL, V2, P686-
dc.description.citedreferenceRami-Porta R, 2007, J THORAC ONCOL, V2, P593-
dc.description.citedreferenceRusch VW, 2007, J THORAC ONCOL, V2, P603-
dc.description.citedreferenceRicci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384-
dc.description.citedreferenceWinkler A, 2007, VIRCHOWS ARCH, V450, P59, DOI 10.1007/s00428-006-0316-0-
dc.description.citedreferenceGoldstraw P, 2006, J THORAC ONCOL, V1, P281-
dc.description.citedreferenceSmith SC, 2006, CANCER RES, V66, P1917, DOI 10.1158/0008-5472.CAN-05-3855-
dc.description.citedreferenceCollins AT, 2005, CANCER RES, V65, P10946, DOI 10.1158/0008-5472.CAN-05-2018-
dc.description.citedreferencePonti D, 2005, CANCER RES, V65, P5506-
dc.description.citedreferenceChoi YL, 2005, GYNECOL ONCOL, V97, P379, DOI 10.1016/j.ygyno.2005.01.018-
dc.description.citedreferenceAbraham BK, 2005, CLIN CANCER RES, V11, P1154-
dc.description.citedreferenceKristiansen G, 2004, J MOL HISTOL, V35, P255-
dc.description.citedreferenceKristiansen G, 2004, PROSTATE, V58, P183, DOI 10.1002/pros.10324-
dc.description.citedreferenceTRAVIS WD, 2004, WHO INT HISTOLOGICAL-
dc.description.citedreferenceKristiansen G, 2003, CLIN CANCER RES, V9, P4906-
dc.description.citedreferenceKristiansen G, 2003, BRIT J CANCER, V88, P231, DOI 10.1038/sj.bjc.6600702-
dc.description.citedreferenceKristiansen G, 2002, AM J PATHOL, V161, P1215-
dc.description.citedreferenceCersosimo RJ, 2002, AM J HEALTH-SYST PH, V59, P611-
dc.description.citedreferenceReya T, 2001, NATURE, V414, P105-
dc.description.citedreferenceFriederichs J, 2000, CANCER RES, V60, P6714-
dc.description.citedreferenceFogel M, 1999, CANCER LETT, V143, P87-
dc.description.citedreferenceCram DS, 1999, DIFFERENTIATION, V64, P237-
dc.description.citedreferenceD`Amico TA, 1999, J THORAC CARDIOV SUR, V117, P736-
dc.description.citedreferenceAigner S, 1998, FASEB J, V12, P1241-
dc.description.citedreferenceRedondo P, 1998, EXP DERMATOL, V7, P175-
dc.description.citedreferenceMountain CF, 1997, CHEST, V111, P1710-
dc.description.citedreferenceAigner S, 1997, BLOOD, V89, P3385-
dc.description.citedreferencePottratz ST, 1996, AM J PHYSIOL-LUNG C, V271, pL918-
dc.description.citedreferencePoncet C, 1996, ACTA NEUROPATHOL, V91, P400-
dc.description.citedreferenceAIGNER S, 1995, INT IMMUNOL, V7, P1557-
dc.description.citedreferenceTRAVIS WD, 1995, CANCER, V75, P191-
dc.description.citedreferenceAKASHI T, 1994, VIRCHOWS ARCH, V425, P399-
dc.description.citedreferenceSAMMAR M, 1994, INT IMMUNOL, V6, P1027-
dc.description.citedreferenceSHIRASAWA T, 1993, DEV DYNAM, V198, P1-
dc.description.citedreferenceFIGARELLABRANGER D, 1993, ACTA NEUROPATHOL, V86, P275-
dc.description.citedreferenceJACKSON D, 1992, CANCER RES, V52, P5264-
dc.description.citedreferenceBEAHRS OH, 1992, AM J COMMITTEE CANC, P115-
dc.description.citedreferenceDROZ D, 1990, AM J PATHOL, V137, P895-
dc.description.citedreferenceFISCHER GF, 1990, J IMMUNOL, V144, P638-
dc.description.citedreferencePIRRUCCELLO SJ, 1986, J IMMUNOL, V136, P3779-
dc.description.citedreferenceZUBROD CG, 1960, J CHRON DIS, V11, P7-
dc.description.tc6-
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Pathology (병리학전공)Journal Papers (저널논문_병리학전공)
Files in This Item:
There are no files associated with this item.
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse